Quality of Life of Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) and Stevens-Johnson Syndrome (SJS) and/or Toxic Epidermal Necrolysis (TEN) Patients

Quality of Life of Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) and Stevens-Johnson Syndrome (SJS) and/or Toxic Epidermal Necrolysis (TEN) Patients

Dyah Aryani Perwitasari,1 Sri Awalia Febriana,2 Ratna Septi Tristiana1 1Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia; 2Department of Dermatology and Venereology, Universitas Gadjah Mada, Yogyakarta, IndonesiaCorrespondence: Dyah Aryani PerwitasariFaculty of Pharmacy, Universi...

Full description

Bibliographic Details
Main Authors:	Perwitasari DA, Febriana SA, Tristiana RS
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-02-01
Series:	Patient Preference and Adherence
Subjects:	dress qol sjs ten skin diseases
Online Access:	https://www.dovepress.com/quality-of-life-of-drug-reaction-with-eosinophilia-and-systemic-sympto-peer-reviewed-article-PPA

Similar Items

Causative drugs and clinical outcome in Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS-TEN overlap in children
by: Gomathy Sethuraman, et al.
Published: (2012-01-01)

Post Herpes Zoster dermatome/s – a therapeutic ground for cutaneous T-cell lymphoma (CTCL) & Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
by: Ajith P. Kannangara
Published: (2015-01-01)

Stevens Johnson Syndrome: Past, Present, and Future Directions Gynecologic Manifestations and Management in SJS/TEN
by: Michelle A. DenAdel, et al.
Published: (2022-07-01)

Clinicoetiological study of Stevens-Johnson syndrome and toxic epidermal necrolysis spectrum and the correlation of SCORTEN with prognosis
by: Amuthavalli Kanagarajan, et al.
Published: (2023-01-01)

Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
by: Allison S. Dobry, et al.
Published: (2022-06-01)

Disease severity and status in Stevens–Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs
by: Rannakoe J. Lehloenya, et al.
Published: (2022-09-01)

A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis
by: Ng QX, et al.
Published: (2018-03-01)

Stevens-Johnson syndrome and toxic epidermal necrolysis in pregnant patients: A systematic review
by: Ajay N. Sharma, BS, et al.
Published: (2020-09-01)

The successful management of SJS/TEN secondary to enfortumab vedotin therapy
by: Rhea Singh, BS, et al.
Published: (2022-06-01)

An alternative model for assessing mortality risk in Stevens Johnson syndrome/toxic epidermal necrolysis using a random forests classifier: A pilot study
by: Omar Shareef, et al.
Published: (2022-12-01)

Editorial: Stevens Johnson syndrome: past, present, and future directions
by: Hajirah N. Saeed, et al.
Published: (2024-03-01)

Increased predisposition of sjs ten in COVID-19 patients, presenting as post COVID complication: Report of two cases
by: Shayna Aulakh, et al.
Published: (2022-01-01)

Steven-Johnson Syndrome
by: Pauline Joy F. Santos, et al.
Published: (2017-07-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Successful Treatment of Carbamazepine-Induced Toxic Epidermal Necrolysis With Clinical Gastrointestinal Involvement: A Case Report
by: Le Quynh Chi, et al.
Published: (2022-04-01)

Oral mucosal Myiasis: A rare association with pediatric SJS-TEN overlap
by: Annie Raizada, et al.
Published: (2021-01-01)

The Profiles of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) Patients in Tertiary Hospital
by: William Andrew Isaac, et al.
Published: (2021-07-01)

From the Cochrane Library: Systemic Interventions for Steven-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN Overlap Syndrome
by: Gaurav Nitin Pathak, et al.
Published: (2024-01-01)

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
by: Paul V. Viscuse, et al.
Published: (2021-03-01)

DRESS and Stevens–Johnson Syndrome Overlap Secondary to Allopurinol in a 50-Year-Old Man—A Diagnostic and Treatment Challenge: Case Report
by: José Dario Martínez, et al.
Published: (2023-11-01)

Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications
by: Mayumi Ueta
Published: (2021-12-01)

Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA
by: Derek Metcalfe, et al.
Published: (2021-07-01)

Severe Cutaneous Adverse Reactions Associated With High-Dose Lamotrigine for Mood Disorders: A Case Series
by: Abigale Clark, et al.
Published: (2022-07-01)

Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition
by: Nicole A. Mifsud, et al.
Published: (2021-04-01)

Correlations between histopathologic findings, serum biomarker levels, and clinical outcomes in Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
by: Donlaporn Chuenwipasakul, et al.
Published: (2023-08-01)

Toxic Epidermal Necrolysis
by: Syed Naveed Ali Shah, et al.
Published: (2020-11-01)

Diclofenac-Serratiopeptidase Combination Induced Stevens – Johnson Syndrome - A Rare Case Report with Review of Literature
by: Saibal Moitra, et al.
Published: (2014-07-01)

Analysis of severity and preventability in patients of—Toxic epidermal necrolysis—A case series
by: Deepa Latha Ciddhavaduta, et al.
Published: (2020-12-01)

Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions
by: S. Veenstra, et al.
Published: (2023-08-01)

Anesthetic management and outcomes of patients with Steven-Johnson Syndrome—A retrospective review study
by: Manjula V Ramsali, et al.
Published: (2021-01-01)

Toxic epidermal necrolysis and Stevens-Johnson syndrome
by: French Lars E, et al.
Published: (2010-12-01)

Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database
by: Fei W, et al.
Published: (2023-08-01)

Epidermal necrolysis (Stevens–Johnson syndrome and toxic epidermal necrolysis): Historical considerations
by: Jean-Claude Roujeau
Published: (2013-12-01)

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis
by: Jiali Cao, et al.
Published: (2023-05-01)

Ivermectin induced Steven–Johnsons syndrome: case report
by: Desmond Aroke, et al.
Published: (2017-05-01)

Severe ocular complications of SJS/TEN and associations among pre-onset, acute, and chronic factors: a report from the international ophthalmology collaborative group
by: Mayumi Ueta, et al.
Published: (2023-06-01)

Stevens-Johnson syndrome and toxic epidermal necrolysis in children
by: Sudip Das, et al.
Published: (2018-01-01)

Role of amniotic membrane transplantation in treating acute ocular manifestations in Steven–Johnson syndrome and its long-term impact
by: Prabhakar Singh, et al.
Published: (2022-01-01)

Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis
by: Shih-Chi Su, et al.
Published: (2013-12-01)

DRUG-INDUCED STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS
by: Dalia Dop, et al.
Published: (2016-12-01)